Evaluación del índice de toxicidad por glucocorticoides en pacientes con Artritis Reumatoide y Lupus
| dc.contributor.advisor | Salas Siado, José | |
| dc.contributor.advisor | Rojano Rada, Jairo | |
| dc.contributor.author | Chimá Bustillo, Silvana | |
| dc.contributor.author | Chacón Guerra, Marco | |
| dc.coverage.spatial | Barranquilla | spa |
| dc.creator.email | silvanachimabustillo@gmail.com | spa |
| dc.creator.email | marcochaconmd@gmail.com | spa |
| dc.date.accessioned | 2023-08-16T16:20:17Z | |
| dc.date.available | 2023-08-16T16:20:17Z | |
| dc.date.created | 2021-05 | |
| dc.description.abstract | Objetivo: Evaluar el GTI en pacientes con AR y LES que asisten a la consulta externa de reumatología de Consalud Barranquilla y Bienestar IPS Riohacha durante el período comprendido entre octubre de 2020-marzo de 2021.Métodos: Se realizó un estudio multicéntrico, prospectivo y transversal en pacientes con AR y LES, que asistieron al área de consulta de reumatología de Consalud Barranquilla y Bienestar IPS Riohacha, durante octubre 2020 - marzo 2021. Resultados: La muestra fue de 95 pacientes, la edad fue 48.1 ± 15.4 años, sexo femenino con 96,8% (n= 92). La prednisona fue el fármaco mayormente utilizado en ambos grupos, siendo mayor en AR 81,2% (n=39) (p<0.002), la dosis de 0-5 mg en AR 70.8% (n=34) y con un tiempo de uso de 1 año en LES 37,2% (n=16). El puntaje del GTI en relación a prednisona fue bajo promedio 90,9% (n=40). El puntaje GTI y dosis fue 6-10 mg bajo promedio 13,6% (n=6) (OR: 5,7 [IC 95%: 1,1-30,0] p <0,05). El puntaje GTI y tiempo de uso mayor a 3 años promedio o superior con 29.8% (n=14) (OR: 5,0 [IC 95%: 1,3-18,6] p <0,05). El puntaje GTI-SLEDAI 2KG actividad leve-severa promedio o superior con 100% (n=12) p< 0,047 (OR: 10,1 [IC 95%: 0,5-188,4] p=0,732). Conclusiones: Los resultados obtenidos apoyan la hipótesis inicial de que el riesgo de desarrollar efectos secundarios y eventos adversos asociados con GC se relacionan de manera directa con el tiempo de uso (superior a 3 años) | spa |
| dc.description.abstractenglish | Objective: To evaluate GTI in patients with RA and SLE who attend outpatient rheumatology consultation at Consalud IPS Barranquilla and Bienestar IPS at Riohacha headquarter in the period between October 2020 and march 2021. Methods: A cross-sectional multicenter study was performed in patients with RA and SLE who attended Rheumatology office at Consalud IPS in Barranquilla and Bienestar IPS in Riohacha in the period between October 2020 and march 2021. Results: A sample of 95 patients, with average of age 48.1±15.4 years, mostly female with 95.8%(n=92). Prednisone was the most used medication in both groups, more reprrsentarive in RA 81.2% (n=39)(p<0.002), For dose 0-5 mg RA 70.8% (n=34), and for usage time of 1 year SLE 37.2%(n=16). The GTI Related to prednisone use was below average 90.9% (n=40). The relationship GTI-dose 6-10mg was below average 13.6%(n=6) (OR: 5,7 [IC 95%: 1,1-30,0] p <0,05); GTI-usage time higher than 3 years was average or higher 29.8% (n=14) (OR: 5,0 [IC 95%: 1,3-18,6] p <0,05) and GTI-SLEDAI 2KG mild to severe activity, average or higher 100% (n=12) p< 0,047 (OR: 10,1 [IC 95%: 0,5-188,4]. Conclusion: The results support the main hypothesis which refers to the risk of developping side effects and adverse events related to GC are directly related to usage time (higher than 3 years) | spa |
| dc.description.sponsorship | Universidad Libre Seccional Barranquilla -- Facultad de Ciencias de la Salud -- Especialización en Medicina Interna | spa |
| dc.format | spa | |
| dc.identifier.uri | https://hdl.handle.net/10901/26148 | |
| dc.relation.references | Guía de Práctica Clínica para el Manejo de Pacientes con Artritis Reumatoide. Sociedad Española de Reumatología; 2019 p. 301 | spa |
| dc.relation.references | Gordon C, Amissah-Arthur MB, Gayed M, Brown S, Bruce IN, D'Cruz D, et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology (Oxford). 2018;57(1): e1-e45. doi:10.1093/rheumatology/kex286 | spa |
| dc.relation.references | Buttgereit F, DaSilva JA, Boers M, Burmester G, Cutolo M, Jacobs J, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis 2002; 61:718–22 | spa |
| dc.relation.references | Fundación Nacional de Osteoporosis. Guía del médico para la prevención y el tratamiento de la osteoporosis. Belle Mead (Nueva Jersey): Excerpta Medica Inc; 1998 | spa |
| dc.relation.references | Klein BE, Klein R, Lee KE, Danforth LG. Consumo de drogas e incidencia de cataratas relacionadas con la edad durante cinco años: el Beaver Dam Eye Study . Ophthalmology 2001; 108: 1670 – 4 | spa |
| dc.relation.references | Miloslavsky EM, Naden RP, Bijlsma WJ, Brogan PA, Brown ES, Brunetta P, et al. Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. Ann Rheum Dis. 2017;76(3):543-546. doi:10.1136/annrheumdis-2016- 210002 | spa |
| dc.relation.references | Gómez Ordóñez S, Gutiérrez Álvarez Ángela M, Valenzuela Plata EL. Corticoides: 60 años después, una asignatura pendiente. Rev. Cienc. salud. 2010; 5(3). Disponible en: https://revistas.urosario.edu.co/index.php/revsalud/article/view/528 | spa |
| dc.relation.references | Ozen G, Pedro S, Wolfe F, Michaud K. Medications associated with fracture risk in patients with rheumatoid arthritis. Ann Rheum Dis. 2019;78(8):1041-1047. doi:10.1136/annrheumdis-2019-215328 | spa |
| dc.relation.references | Dardonville Q, Salguiero E, Rousseau V, Chebane L, Faillie J, Gautier S, et al. Druginduced osteoporosis/osteomalacia: analysis in the French and Spanish pharmacovigilance databases. Eur J Clin Pharmacol. 2019;75(12):1705-1711. doi:10.1007/s00228-019-02743-9 | spa |
| dc.relation.references | Ugarte A, Danza A, Ruiz-Irastorza G. Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions. Curr Opin Rheumatol. 2018;30(5):482-489. doi:10.1097/BOR.0000000000000527 | spa |
| dc.relation.references | Yang SC, Lai YY, Huang MC, Tsai CS, Wang JL. Corticosteroid dose and the risk of opportunistic infection in a national systemic lupus erythematosus cohort. Lupus. 2018;27(11):1819-1827. doi:10.1177/0961203318792352 | spa |
| dc.relation.references | Moya F, Pineda L, Garcia M. Impact of Chronic Glucocorticoid Treatment on Cardiovascular Risk Profile in Patients with Systemic Lupus Erythematosus. J Clin Rheumatol, 2016; 22(1): 8-12. doi: 10.1097 / RHU.0000000000000335 | spa |
| dc.relation.references | Youssef J, Novosad SA, Winthrop KL. Infection Risk and Safety of Corticosteroid Use. Rheum Dis Clin North Am. 2016;42(1):157-x. doi: 10.1016/j.rdc.2015.08.004 | spa |
| dc.relation.references | Benítez S, Aveiro A. Complicaciones del uso prolongado de corticoides: Cushing iatrogénico. Rev. virtual Soc. Parag. Med. Int. 2018; 05(02): 30-7. https://doi.org/10.18004/rvspmi/2312-3893/2018.05(02)30-037 | spa |
| dc.relation.references | Schultz H, Krogh B, Lommer P, Kryger A, Pedersen-Bjergaard U. Early incidence of glucocorticoid-induced diabetes in patients with brain tumors: a retrospective study of the first 7 days of treatment. Neuro-Oncology Practice. 2018; 5: 170–175, doi.org/10.1093/nop/npx027 | spa |
| dc.relation.references | Cruz A, Rodríguez D. Caracterización de eventos adversos con medicamentos corticosteroides reportados al Programa Nacional de Farmacovigilancia en Colombia (2005-2016) [Magister en Toxicología]. Universidad de ciencias aplicadas y ambientales; 2018 | spa |
| dc.relation.references | Curtis JR, Westfall AO, Allison J, Bijlsma J, Freeman A, George V, et al. Populationbased assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006;55(3):420-426. doi:10.1002/art.21984 | spa |
| dc.relation.references | Ramamoorthy, S., & Cidlowski, J. A. Corticosteroids. Rheumatic Disease Clinics of North America. 2016; 42(1):15–31. doi: 10.1016/j.rdc.2015.08.002 | spa |
| dc.relation.references | Cosío B, Torrego A, Torrego B, Adcocket M. Mecanismos moleculares de los glucocorticoides. Arch Bronconeumol. 2005;41(1):34-41. DOI: 10.1157/13070282 | spa |
| dc.relation.references | Groeneweg FL, Karst H, de Kloet ER, et al. Mineralocorticoid and glucocorticoid receptors at the neuronal membrane, regulators of nongenomic corticosteroid signaling. Mol Cell Endocrinol. 2012; 350:299–309. doi: 10.1016 / j.mce.2011.06.020 | spa |
| dc.relation.references | Mullol J, Pujols L, Picado C. Mecanismos de acción de los glucocorticoides. Aplicación al tratamiento de la inflamación respiratoria. Arch bronconeumol. 1996; 32: 527-534 | spa |
| dc.relation.references | Samarasinghe RA, Witchell SF, DeFranco DB. Cooperativity and complementarity: synergies in non-classical and classical glucocorticoid signaling. Cell Cycle. 2012; 11:2819–27. doi: 10.4161/cc.21018 | spa |
| dc.relation.references | Grad I, Picard D. The glucocorticoid responses are shaped by molecular chaperones. Mol Cell Endocrinol. 2007; 275:2–1. doi:10.1016/j.mce.2007.05.018 | spa |
| dc.relation.references | Poetker, D. M., & Reh, D. D. A Comprehensive Review of the Adverse Effects of Systemic Corticosteroids. Otolaryngologic Clinics of North America. 2010; 43(4):753–768. doi: 10.1016/j.otc.2010.04.003 | spa |
| dc.relation.references | Rawlins MD, Thompson JW. Pathogenesis of adverse drug reactions. Davies’s textbook of adverse drug reactions. 4ta edición. New York, USA: Oxford University Press; 1977. p. 44 | spa |
| dc.relation.references | Meyboom R, Lindquist M, Egberts A. An ABC of drug related problems. Drug Safety. 2000; 22(6):416-423. DOI: 10.2165 / 00002018-200022060-00001 | spa |
| dc.relation.references | Hoes J, Goes M, Raalte D, Zijl N, Uyl D, Lems W, et al. Glucose tolerance, insulin sensitivity and β-cell function in patients with rheumatoid arthritis treated with or without low-to-medium dose glucocorticoids. Ann Rheum Dis. 2011; 70:1887–1894. DOI: 10.1136/ ard.2011.151464 | spa |
| dc.relation.references | Aronson J.K. Corticosteroids— glucocorticoids. Meyler's Side Effects of Drugs, Sixteenth Edition Elsevier 2016; 594 -657 | spa |
| dc.relation.references | Gutiérrez-Polo R. Osteoporosis inducida por glucocorticoides. Anales Sis San Navarra. 2003; 26 (3): 63-80 | spa |
| dc.relation.references | Weinstein, R. S., Glucocorticoid-Induced Osteoporosis and Osteonecrosis. Endocrinology and Metabolism Clinics of North America. 2012; 41(3), 595–611. DOI: 10.1016 / j.ecl.2012.04.004 | spa |
| dc.relation.references | Johannes W.G, Jacobs and Johannes W.J. Bijlsma. Tratamiento con glucocorticoides. Firestein G, Budd R, ShGabriel S, McInnes I, O'Dell J. Kelley y Firestein. Tratado de reumatología. 10ma Ed. España: Elsevier; 2018. p.1329- 1344 | spa |
| dc.relation.references | Youssef, J., Novosad, S. A., & Winthrop, K. L, Infection Risk and Safety of Corticosteroid Use. Rheumatic Disease Clinics of North America. 2016; 42(1), 157– 176. DOI: 10.1016 / j.rdc.2015.08.004 | spa |
| dc.relation.references | Dubovsky A, Arvikar S, Stern T, Axelrod L. The Neuropsychiatric Complications of Glucocorticoid Use: Steroid Psychosis Revisited. Psychosomatics. 2012; 53(2):103- 15. DOI: 10.1016 / j. psym.2011.12.007 | spa |
| dc.relation.references | Carnahan MC, Goldstein DA. Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol. 2000; 11:478–83. DOI: 10.1097/00055735-200012000-00016 | spa |
| dc.relation.references | Duru, N, Van Der Goes MC, Jacobs JWG, Andrews T, Boers M, Buttgereit F, et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Annals of the Rheumatic Diseases. 2013; 72(12), 1905–1913. DOI: 10.1136 / annrheumdis-2013-203249 | spa |
| dc.relation.references | Situación de la artritis reumatoide en Colombia 2016, cuenta de alto costo CAC. Fondo colombiano de Enfermedades de Alto Costo. ISSN: 2590-9037. edición anual. Bogotá DC, 2017 | spa |
| dc.relation.references | Aletaha D, Neogi T, Silman A, Funovits J, Felson D, Bingham C, et al. 2010 Rheumatoid Arthritis Classification Criteria: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis & Rheumatism.2010; 62 (9): 2569–2581. DOI: 10.1002 / art.27584 | spa |
| dc.relation.references | Petri M, Orbai A, Alarcón G, Gordon C, Merrill J, Fortin P, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Artritis Rheum. 2012; 64(8): 2677–2686. DOI: 10.1002 / art.34473 | spa |
| dc.relation.references | Pincus T, Yazici Y, Bergman M. RAPID3, an index to assess and monitor patients with rheumatoid arthritis, without formal joint counts: similar results to DAS28 and CDAI in clinical trials and clinical care. Rheum Dis Clin North Am. 2009;35(4):773-8, viii. DOI: 10.1016 / j.rdc.2009.10.008 | spa |
| dc.relation.references | Touma Z, Gladman D, Su J, Anderson N, Urowitz M. A novel lupus activity index accounting for glucocorticoids: SLEDAI-2K glucocorticoid index. Rheumatology. 2018; 57:1370-1376. https://doi.org/10.1093/rheumatology/key103 | spa |
| dc.relation.references | Blanco-Moralesa E, Bravo-Ferrer J, Rubio E, Gil E, Gantes M. Glucocorticoides en artritis reumatoide: ¿casi siempre o casi nunca? Reumatol Clin. 2011;7(6):407–411. DOI: 10.1016/j.reuma.2011.01.008 | spa |
| dc.relation.references | Mei Z, Grummer-Strawn LM, Pietrobelli A, Goulding A, Goran MI, Dietz WH. Validity of body mass index compared with other body-composition screening indexes for the assessment of body fatness in children and adolescents. American Journal of Clinical Nutrition. 2002; 7597–985. DOI:10.1093/ajcn/75.6.978 | spa |
| dc.relation.references | Urquizo-Ayala G., Arteaga-Coariti R. Diabetes e hiperglicemia inducida por corticoides. Rev Med La Paz. 2017, 23(1):60-68 | spa |
| dc.relation.references | Tobaru-Miyashiro L, Guzmán-Ahumada M. Retinopatía diabética. Diagnóstico. 2019; 58(2): 85-90 | spa |
| dc.relation.references | Thomas, MC; Brownlee M, Susztak K, Sharma K, Jandeleit-Dahm, KAM, Zoungas S, Rossing, P, Groop PH, Cooper ME. Diabetic kidney disease. Nat. Rev. Dis. Prim. 2015; 1: 15018. DOI:10.1038/nrdp.201518 | spa |
| dc.relation.references | Botas M., Cervell D., Rodríguez A., Vicente S., Fernández L. Actualización en el diagnóstico, tratamiento y prevención de la neuropatía diabética periférica. Angiología. 2016 | spa |
| dc.relation.references | Whelton P, Carey R, Aronow W, Casey D , Collins K , Dennison C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018; 71 (6): 1269-1324. DOI: 10.1161 / HYP.0000000000000066 | spa |
| dc.relation.references | Gómez E, Bragulat E. Hipertensión arterial, crisis y emergencia hipertensivas: actitud en urgencias. Emergencias. 2010; 22:209-219 | spa |
| dc.relation.references | Ulises M, Delgado L, Giraldo N, Urueña P, Franco S, Hernández O. Síndrome de encefalopatía posterior reversible. Biomédica. 2017;37(Supl.1):12-9. DOI: https://doi.org/10.7705/biomedica.v37i2.3299 | spa |
| dc.relation.references | Saadoun D. Corticoterapia sistémica. EMC. 2020, E – 7-1200. Doi:10.1016/S1636- 5410(20)43348-3 | spa |
| dc.relation.references | Barberán M, Campusano C, Trincado P, Oviedo S, Brantes S, Sapunar J. Recomendaciones para el uso correcto de densitometría ósea en la práctica clínica. Consenso de la Sociedad Chilena de Endocrinología y Diabetes. Rev Med Chile. 2018; 146: 1471-1480. http://dx.doi.org/10.4067/s0034-98872018001201471 | spa |
| dc.relation.references | Romero M., Pérez A., Turrión A., Moruno H. Protocolo diagnóstico diferencial de las miopatías en la artritis reumatoide. Medicine. 2017;12(28):1672-6 | spa |
| dc.relation.references | Gil L, Sarmiento M. Psicosis inducida por esteroides. Rev. Colomb. Psiquiat., vol. XXXVI / No. 3 / 2007 | spa |
| dc.relation.references | Martín-Aragón S. Anabolizantes Revisión. Departamento de Farmacología, Facultad de Farmacia, Universidad Complutense de Madrid. 2011, 30 (1): 54-58 | spa |
| dc.relation.references | Da Silva J, Bijlsma J. Optimizing glucocorticoid therapy in rheumatoid arthritis. Rheumatic Disease Clinics of North America. 2000; 26 (4): 859-879. DOI: 10.1016 / s0889-857x (05) 70173-3 | spa |
| dc.relation.references | Águila M, Nava K. Úlcera gástrica perforada ¿Qué camino a seguir?: presentación de un caso y revisión de la literatura. Rev Med La Paz. 2015, 21(2): 54-59. DOI: 10.1016 / s0889-857x (05) 70173-3 | spa |
| dc.relation.references | Solis-Cartas U, Calvopiña S. Comorbilidades y calidad de vida en Osteoartritis. Revista Cubana de Reumatología. 2018; 20(2): 1-14. http://dx.doi.org/10.5281/zenodo.1188918 | spa |
| dc.relation.references | Machado-Alba J, Ruiz AF, Medina DA. The epidemiology of rheumatoid arthritis in a cohort of Colombian patients. Rev Colomb Reumatol. 2015; 22(3):148–152. http://dx.doi.org/10.1016/j.rcreu.2015.05.006 | spa |
| dc.relation.references | Siebert S, Lyall D, Mackay D, Porter D, McInnes I, Sattar N, Pell J. Characteristics of rheumatoid arthritis and its association with major comorbid conditions: crosssectional study of 502 649 UK Biobank participants. RMD Open. 2016; 2(1): e000267. DOI: 10.1136/ rmdopen-2016-000267 | spa |
| dc.relation.references | Fernández-Ávila DG, Bernal-Macías S, Rincón-Riaño DN, Gutiérrez JM, Rosselli D. Prevalence of systemic lupus erythematosus in Colombia: data from the national health registry 2012–2016. Lupus (2019) 0, 1–6. DOI: 10.1177 / 0961203319864168 | spa |
| dc.relation.references | Gergianakia I, Bortoluzzib A, Bertsias G. Update on the epidemiology, risk factors, and disease outcomes of systemic lupus erythematosus. Best Practice & Research Clinical Rheumatology. 2018, 1-18. DOI: 10.1016/j.berh.2018.09.004 | spa |
| dc.relation.references | Anyfanti P, Gavriilaki E, Douma S, Gkaliagkousi E. Endothelial Dysfunction in Patients with Rheumatoid Arthritis: The Role of Hypertension. Curr Hypertens Rep. 2020, 22:56. DOI: 10.1007/s11906-020-01064-y | spa |
| dc.relation.references | Legge A, Blanchard C, Hanly J. Physical activity and sedentary behavior in patients with systemic lupus erythematosus and rheumatoid arthritis. Open Access Rheumatol. 2017; 9: 191–200. Doi:10.2147/OARRR.S148376 | spa |
| dc.relation.references | Talsania M, Scofield R. Menopause and rheumatic disease. Rheum Dis Clin North Am. 2017; 43(2): 287–302. DOI: 10.1016 / j.rdc.2016.12.011 | spa |
| dc.relation.references | Baker J, Sauer B, Teng C, George M, Cannon G, Ibrahim S, et al. Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis Is Associated with Changes in Blood Pressure. J Clin Rheumatol. 2018; 24(4): 203–209. DOI: 10.1097 / RHU.0000000000000736 | spa |
| dc.relation.references | González LA, Molina JF. Evaluación de la inflamación en el laboratorio. Rev.Colomb.Reumatol. 2010; 17 (1): 35-47 | spa |
| dc.relation.references | Dima A, D Opris D, Jurcut C, Baicus C. Is there still a place for erythrocyte sedimentation rate and C-reactive protein in systemic lupus erythematosus? Lupus. 2016; 0:1–7. DOI: 10.1177 / 0961203316651742 | spa |
| dc.relation.references | Ballesteros JG, Giraldo R, Santos A, Bello-Gualteros JM, Rueda J, Saldarriaga EL, et al. Correlation between rapid-3, DAS28, CDAI and SDAI as a measure of disease activity in a cohort of Colombian patients with rheumatoid arthritis. Clinical Rheumatology. 2017; 36:1143–1148. DOI:10.1007/s10067-016-3521-5 | spa |
| dc.relation.references | Touma Z, Gladman D, Su J, Anderson N, Urowitz M. A novel lupus activity index accounting for glucocorticoids: SLEDAI-2K glucocorticoid index. Rheumatology. 2018; 57:1370-1376. doi:10.1093/rheumatology/key103 | spa |
| dc.relation.references | Conigliaroa P, Cesareob M, Chimentia M, Triggianesea P, Canofaria C, Barbatoa C, et al. Take a look at the eyes in Systemic Lupus Erythematosus: A novel point of view. Autoimmunity Reviews 18. 2019, 247–254. DOI: 10.1016/j.autrev.2018.09.011 | spa |
| dc.relation.references | Bautista-Molano W, Fernández-Avila D, Jiménez R, Cardozo R, Marín A, Soler MP, et al. Epidemiological Profile of Colombian Patients With Rheumatoid Arthritis in a Specialized Care Clinic. Reumatol Clin. 2016; 1-6. DOI: 10.1016 / j. reuma.2015.11.009 | spa |
| dc.relation.references | Keyßer G. Sicherheitsaspekte der Therapie mit Glukokortikoiden bei rheumatoider Arthritis. Z Rheumatol. 2021; 11:1–8. doi:10.1007/s00393-021-00972-x | spa |
| dc.relation.references | Kasturi S, Sammaritano L. Corticosteroids in Lupus. Rheum Dis Clin North Am. 2016; 42(1):47-62, viii. DOI: 10.1016 / j.rdc.2015.08.007 | spa |
| dc.relation.references | Santamaría-Alza Y, Zulney J, Fajardo-Rivero J, Figueroa CL. Systemic lupus erythematosus, gender differences in Colombian patients. Clinical Rheumatology. 2018; 37: 2423–2428. DOI: 10.1007 / s10067-018-4161-8 | spa |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | spa |
| dc.subject | Artritis | spa |
| dc.subject | Lupus | spa |
| dc.subject | Glucocorticoides | spa |
| dc.subject | Toxicidad | spa |
| dc.subject | Índices | spa |
| dc.subject.lemb | Glucocorticoides | spa |
| dc.subject.lemb | Toxicidad | spa |
| dc.subject.lemb | Lupus Eritematoso Sistémico | spa |
| dc.subject.lemb | Artritis Reumatoide | spa |
| dc.subject.subjectenglish | Arthritis | spa |
| dc.subject.subjectenglish | Lupus | spa |
| dc.subject.subjectenglish | Glucocorticoids | spa |
| dc.subject.subjectenglish | Toxicity | spa |
| dc.subject.subjectenglish | Index | spa |
| dc.title | Evaluación del índice de toxicidad por glucocorticoides en pacientes con Artritis Reumatoide y Lupus | spa |
| dc.title.alternative | Evaluation of the glucocorticoid toxicity index in patients with Rheumatoid Arthritis and Lupus | spa |
| dc.type.driver | info:eu-repo/semantics/bachelorThesis | spa |
| dc.type.local | Tesis de Especialización | spa |